Generation of Persister Cells of Pseudomonas aeruginosa and Staphylococcus aureus by Chemical Treatment and Evaluation of Their Susceptibility to Membrane-Targeting Agents

A patient finishes a full course of antibiotics. The infection clears. Then, weeks later, it comes back — not because the bacteria evolved a new defense, not because anything in their DNA changed, but because a small fraction of them simply went to sleep. They slowed their metabolism to a near standstill, waited out the drug, and when the coast was clear, they woke up and started dividing again. That distinction — resistance versus tolerance — is one of the most important and underappreciated problems in infectious disease today. These sleeping bacteria are called persister cells. They are not a mutant strain. They are a phenotypic variant, a temporary state that any bacterium in a population can slip into. The tolerance disappears when the cells wake up — their offspring are just as drug-sensitive as the original population. That reversibility makes persisters invisible to standard susceptibility testing, which looks for heritable resistance. It also makes them dangerous in chronic infections, where a residual persister pool can survive therapy and re-seed the infection once treatment stops. Grassi and colleagues highlighted two species where this matters enormously: Pseudomonas aeruginosa and Staphylococcus aureus. Both form biofilms and are commonly implicated in relapsing chronic infections, such as lung infections in cystic fibrosis and wound infections associated with medical devices. In biofilms, persister levels can reach roughly one percent of the population. That sounds small, but when you are trying to achieve complete eradication, a one percent survivor fraction is a clinical problem. The field urgently needs agents that can target dormant, growth-independent bacteria. Before you can find those agents, though, you need a reliable way to make persister cells in the lab. That is exactly what Grassi et al. set out to build. Their tool of choice was a molecule called carbonyl cyanide m-chlorophenylhydrazone, or CCCP — a protonophore, meaning it disrupts the bacterial membrane's energy system. Bacteria maintain a proton gradient across their inner membrane, a kind of electrochemical pressure difference, that powers the enzymes making adenosine triphosphate. CCCP collapses that gradient. Without it, cells lose their metabolic drive and go quiet. The key insight behind this study is that forcing bacteria into that quiet state chemically, rather than waiting for them to enter it naturally, gives you a controllable, high-yield way to generate persister-enriched cultures. The protocol required careful calibration. The team grew both Pseudomonas aeruginosa and Staphylococcus aureus to stationary phase, then exposed them to a range of CCCP concentrations to find doses that suppressed metabolism without simply killing the cells. For Pseudomonas aeruginosa, the sweet spot was 200 micrograms per milliliter for three hours. For Staphylococcus aureus, it was 400 micrograms per milliliter for the same duration. After CCCP exposure, the cells were washed to remove the drug and challenged with standard bactericidal antibiotics. The results confirmed the method worked. Pseudomonas aeruginosa pretreated with CCCP showed a five-thousand-fold increase in survival to ciprofloxacin compared to untreated controls. Meropenem tolerance rose two-hundred-fold, with thirty-five percent of the starting population surviving. Staphylococcus aureus showed roughly sixty percent survival to levofloxacin and about a five-hundred-fold increase in gentamicin tolerance. These are not marginal effects; these are populations that antibiotics essentially cannot touch. However, survival to antibiotics alone does not prove the cells are persisters rather than just dead cells that do not plate. To demonstrate genuine dormancy, Grassi et al. brought in two complementary measurement tools. The first was isothermal microcalorimetry, a technique that detects the tiny heat output of living bacteria as a continuous, real-time proxy for metabolic activity. Untreated stationary-phase cultures of both species produced characteristic heat flow patterns over twenty-four hours. CCCP-treated cultures produced only basal heat, less than five microwatt-hours, indicating a near-complete global suppression of metabolism. The second tool was flow cytometry using a dye called RedoxSensor Green, which fluoresces when reduced by bacterial reductases, enzymes whose activity is tied to respiration. In CCCP-treated populations of both species, RedoxSensor Green fluorescence dropped by approximately threefold relative to untreated controls. Two independent measurements, one whole-population and one single-cell, pointed to the same conclusion: these cells had fundamentally shut down. The critical question was whether that shutdown was reversible. If the cells were just dead, no drug would matter, and the experiment would tell you nothing useful. After CCCP washout and transfer to fresh nutrient medium, both species showed a reproducible lag before metabolic activity resumed—about one and a half hours for Pseudomonas aeruginosa and one hour for Staphylococcus aureus in time to peak heat production. After that lag, growth resumed. When Grassi et al. tested the antibiotic susceptibility of those revived populations, minimum inhibitory concentrations and minimum bactericidal concentrations were identical to untreated controls. The cells woke up sensitive. Metabolic reactivation and the return of antibiotic susceptibility happened together, which is precisely what you expect from true persister biology rather than from dead-cell contamination. Now, the team had a reliable, high-yield source of confirmed dormant bacteria. The next question was the one with therapeutic stakes: what, if anything, can kill them? The hypothesis was mechanistically motivated. Most bactericidal antibiotics work by interfering with processes that require active cell growth, like DNA replication, cell wall synthesis, and protein production. Persisters have paused all of that, so those drugs have nothing to grab. However, antimicrobial peptides, or AMPs, and some peptide-based clinical antibiotics work differently. They physically disrupt the bacterial membrane — a target that exists whether or not the cell is actively dividing. Membrane disruption does not require metabolic cooperation from the bacterium. On paper, that should make membrane-targeting agents candidates for killing dormant cells. The data largely supported this, with one important exception. Three structurally distinct AMPs — C5, Den-SB056, and TB-L1FK — were tested against CCCP-induced persisters of both species. All three eradicated persister-enriched cultures to the limit of detection, just ten colony-forming units per milliliter, within one and a half to three hours. Their bactericidal concentrations against persisters were essentially the same as against untreated cells. For Pseudomonas aeruginosa, C5 and Den-SB056 had minimum bactericidal concentrations of zero point eighty-seven micromolar each; TB-L1FK came in at fourteen micromolar. For Staphylococcus aureus, C5 was zero point eighty-seven micromolar, Den-SB056 was one point seventy-five micromolar, and TB-L1FK fell between three point five and seven micromolar. Dormancy did not protect the cells from any of the three peptides, across either Gram-negative or Gram-positive species. Colistin, a polymyxin antibiotic used clinically against Gram-negative infections, also performed well. Against Pseudomonas aeruginosa persisters, it achieved complete killing at three point five micromolar — only a twofold increase over the one point seventy-five micromolar needed for untreated cells. That is a modest shift, well within the range where the drug could still be clinically relevant. Daptomycin, however, told a different story. This lipopeptide antibiotic targets Gram-positive membranes and is used clinically against Staphylococcus aureus. Against CCCP-induced Staphylococcus aureus persisters, its minimum bactericidal concentration jumped from seven micromolar to one hundred twelve micromolar — a sixteen-fold increase. The paper also notes that this made daptomycin thirty-two to sixty-four times less potent than the tested AMPs against the same persister population. The membrane-targeting logic held for AMPs and colistin, but not for daptomycin. The implication is that the specific way a molecule engages the membrane determines whether dormancy protects against it — mechanistic category alone is not enough. That contrast is the most practically important result in the paper. It informs researchers screening for anti-persister therapeutics that not all membrane-active agents are equivalent against dormant cells. This brings the study back to the platform itself. One reason this work matters beyond its specific findings is the quality of the persister-enriched cultures it produces. Previous methods, often based on antibiotic challenge to select for survivors, yield low persister frequencies and large populations of dead cells that can mask or distort activity readouts. The CCCP method generates twenty to sixty percent persister fractions with negligible dead-cell contamination. This gives drug discovery experiments a much cleaner signal. You are testing candidate molecules against confirmed dormant cells, not against a heterogeneous mix where interpretation is murky. The field now has a reproducible, well-characterized tool for generating persister populations from two of the most clinically significant bacterial species. The immediate priority is finding more membrane-active molecules that retain full potency regardless of metabolic state and screening them rigorously using exactly this kind of platform. Antimicrobial peptides look like a promising template. Daptomycin's failure against Staphylococcus aureus persisters is a warning that clinical use alone is not a guide. The biology of dormancy sets its own terms, and the search for drugs that can meet those terms now has a better place to start. This lecture was created by ennepō. Go to https://ennepo.ai to Discover, Create and Follow the latest research in your field. Read when you can. Listen when you want to.